Evidence map›Paper›PMID 39968062›Full record

ArticleInternational journal of nanomedicine2025

Two-Dimensional MXenes Surface Engineering Nanoplatform for PTT-Chemotherapy Synergistic Tumor Therapy.

Yang Dong, Liang Guo, Lu Song, Tingting Liu, Gang Zheng, Meizhu Zheng, Baojiang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang Dong *Department of Breast Surgery, Breast Cancer Center, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, 271000, People's Republic of China.
Liang Guo *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, People's Republic of China.
Lu SongDepartment of Breast Surgery, Breast Cancer Center, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, 271000, People's Republic of China.
Tingting LiuDepartment of Breast Surgery, Breast Cancer Center, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, 271000, People's Republic of China.
Gang ZhengDepartment of Breast Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China.
Meizhu ZhengDepartment of Breast Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China.
Baojiang LiDepartment of Breast Surgery, Breast Cancer Center, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, 271000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) has a high early recurrence rate and poor prognosis. Given its insensitivity to traditional systemic chemotherapy, there is an urgent need for new therapeutic strategies for effective treatment. This paper reports the development of a novel two-dimensional MXene composite nanoplatform for efficient synergistic chemotherapy and photothermal therapy of TNBC. Results: To achieve surface functionalization of MXene, we developed a surface nanopore engineering strategy, enabling the uniform coating of a thin mesoporous silica layer on the two-dimensional Ti Conclusion: This study provides a new strategy for developing MXene-based composite nano drug delivery systems to effectively combat TNBC.

Indexed as

Antineoplastic AgentsPhotothermal TherapyTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCombined Modality TherapyDoxorubicinDrug Delivery SystemsDrug LiberationFemaleHumansMiceMice, Inbred BALB CMice, NudeNanoporesSilicon DioxideAntineoplastic AgentsDoxorubicinSilicon DioxideTitaniumtitanium carbidechemotherapymesoporous silicaphotothermal therapysynergistic therapyTi3C2 MXene

Identifiers

PMID39968062
PMCPMC11834670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.